Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
2005
Cetrorelix and Its Effects on Prostate Cancer Cell Adhesion
Sample size: 4
publication
Evidence: moderate
Author Information
Author(s): Yates C, Wells A, Turner T
Primary Institution: University of Pittsburgh and Tuskegee University
Hypothesis
The LHRH analogue Cetrorelix would abrogate EGFR signalling, leading to increased E-cadherin levels and decreased invasiveness in prostate cancer cells.
Conclusion
Cetrorelix increases cell adhesion in prostate cancer cells by altering EGFR signalling.
Supporting Evidence
- Cetrorelix reduced the invasiveness of DU-145 WT cells from 100% to 23±14%.
- Cetrorelix increased E-cadherin levels in DU-145 WT cells.
- EGFR levels were significantly reduced after Cetrorelix treatment.
Takeaway
Cetrorelix helps prostate cancer cells stick together better, which could stop them from spreading.
Methodology
The study used flow cytometry and invasion assays to measure the effects of Cetrorelix on DU-145 prostate cancer cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website